BSE: GLAXO - GlaxoSmithKline Pharmaceuticals Limited

Доходность за полгода: +36.73%

График акции GlaxoSmithKline Pharmaceuticals Limited


О компании

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally.

Подробнее
The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.

P/E 49.44
P/S 7.04
P/BV 10.29
EV/EBITDA 24.13
EBITDA 7.32
Цена ао 2698.95
Дивиденд ао 32
Див.доход ао 2.3
Сайт https://india-pharma.gsk.com
Выручка 31.28
Число акций ао 0.16941 млрд
Валюта inr
ISIN INE159A01016
Sector Health Care
Industry Pharmaceuticals
Валюта отчета inr
Изменение цены за день: -0.3301% (2726.5)
Изменение цены за неделю: +0.2398% (2711)
Изменение цены за месяц: -3.08% (2803.95)
Изменение цены за 3 месяца: +2.46% (2652.3)
Изменение цены за полгода: +36.73% (1987.45)
Изменение цены за год: +80.16% (1508.4)
Изменение цены за 3 года: +74.74% (1555.15)
Изменение цены за 5 лет: +126.7% (1198.7)
Изменение цены с начала года: +32.58% (2049.65)

Недооценка

Название Значение Оценка
P/S 6.9 1
P/BV 12.88 1
P/E 36.73 5
EV/EBITDA 24.13 5
Итого: 4.63

Эффективность

Название Значение Оценка
ROA, % 15.34 5
ROE, % 27.73 8
Итого: 4.5

Дивиденды

Название Значение Оценка
Div yield, % 8.57 10
DSI 0.9286 9.29
Итого: 6.61

Долг

Название Значение Оценка
Debt/EBITDA 0.0172 10
Итого: 10

Импульс роста

Название Значение Оценка
Доходность Revenue, % 6.75 1
Доходность Ebitda, % 23.53 4
Доходность EPS, % 11.31 2
Итого: 5

Руководитель Должность Оплата Год рождения
Mr. Bhushan Akshikar MD & Executive Director 32.37M
Mr. Juby Chandy Whole-Time Director & CFO 54.12M 1977 (47 лет)
Mr. Amit G. Pandey Executive Vice President of Legal N/A
Ms. Simrat Sohal Vice President of Ethics & Compliance N/A
Mr. Chinmay Sharma Executive Vice President of Human Resources N/A
Ms. Sukanya Choudhary Executive Vice-President of Regulatory Affairs N/A
Ms. Aparajita Rajput Vice President of Technology
Mr. Ajay Avinash Nadkarni VP of Administration & Real Estate and Company Secretary
Mr. Ransom D'Souza Executive Vice President of Communications & Government Affairs
Mr. Shourov Mukherjee Executive Vice-President of Adult Vaccines

Адрес: India, Mumbai, GSK House - открыть в Google картах, открыть Яндекс картах
Сайт: https://india-pharma.gsk.com